May 23, 2023

Michael Nevradakis, Ph.D. on May 19, 2023 writing for The Defender/Children’s Health Defense states:

• “During Thursday’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting, committee members and medical experts raised concerns about premature births identified during Pfizer’s clinical trials. 
• The FDA is expected to issue a final decision on the vaccine in August. If approved, it would become the first RSV vaccine authorized for pregnant women”.

The article continues with comments “on the FDA’s recommendation of Pfizer’s RSV vaccine, Dr. Peter McCullough, a cardiologist, told The Defender:

• “This product represents an unprecedented attempt to vaccinate mothers for no benefit to them and only theoretical efficacy in babies. In the trial, less than 2% of infants at any time point contracted RSV, which is easily treatable with nebulizers.
• “Pregnancies should not be threatened with novel vaccines for uncommon and low-risk infantile illnesses.
• “Widespread use of this reactogenic vaccine can be expected to cause fetal loss in some unfortunate women. A single case of pregnancy termination would not be worth the population being vaccinated.”

Access the complete article here

____________________________________________________________________________